naxitamab
Sign in to saveAlso known as Danyelza, naxitamab-gqgk
Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.
Medication
- Generic name
- Naxitamab
- Brand names
- Danyelza
- Drug class
- Glycolipid Disialoganglioside-directed Antibody, Glycolipid Disialoganglioside-directed Antibody Interactions
- Route
- Intravenous
- Type
- Human Prescription Drug
- Manufacturer
- BTG International Inc.
Indications: 1 INDICATIONS AND USAGE DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have… (per FDA label)
Clinical Trials
15 registered- PHASE2WITHDRAWNNaxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.Y-mAbs Therapeutics · NCT04909515
- PHASE2NOT_YET_RECRUITINGPatients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5Shaare Zedek Medical Center · NCT07537400
- RECRUITINGAdding Of Naxitamb In Induction Therapy For High Risk NeuroblastomaGuangzhou Women and Children's Medical Center · NCT06574698
- PHASE2RECRUITINGNaxitamab Added to Induction for Newly Diagnosed High-Risk NeuroblastomaGiselle Sholler · NCT05489887
- PHASE2COMPLETEDA Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory NeuroblastomaFundació Sant Joan de Déu · NCT06438614
- PHASE1RECRUITINGFeasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaSteven DuBois, MD · NCT07027748
~2 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.
The most common adverse reactions include injection site reactions or infusion-related reactions, pain, tachycardia (fast heart beats), vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability.
Excerpted from Wikipedia’s “naxitamab” article, available under the CC BY-SA 4.0 licence.